These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25247322)

  • 1. Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers.
    Gill MD; Bramble MG; Hull MA; Mills SJ; Morris E; Bradburn DM; Bury Y; Parker CE; Lee TJ; Rees CJ
    Br J Cancer; 2014 Nov; 111(11):2076-81. PubMed ID: 25247322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme.
    Gill MD; Bramble MG; Rees CJ; Lee TJ; Bradburn DM; Mills SJ
    Br J Cancer; 2012 Jul; 107(3):417-21. PubMed ID: 22782347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
    Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
    Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive impact of a faecal-based screening programme on colorectal cancer mortality risk.
    Ibáñez-Sanz G; Milà N; Vidal C; Rocamora J; Moreno V; Sanz-Pamplona R; Garcia M;
    PLoS One; 2021; 16(6):e0253369. PubMed ID: 34191813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme.
    Morris EJ; Whitehouse LE; Farrell T; Nickerson C; Thomas JD; Quirke P; Rutter MD; Rees C; Finan PJ; Wilkinson JR; Patnick J
    Br J Cancer; 2012 Aug; 107(5):757-64. PubMed ID: 22850549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
    George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
    Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
    Mlakar DN; Bric TK; Škrjanec AL; Krajc M
    Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there biological differences between screen-detected and interval colorectal cancers in the English Bowel Cancer Screening Programme?
    Walsh E; Rees CJ; Gill M; Parker CE; Bevan R; Perry SL; Bury Y; Mills S; Bradburn DM; Bramble M; Hull MA
    Br J Cancer; 2016 Jul; 115(2):261-5. PubMed ID: 27219017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screen-detected and interval colorectal cancers in England: Associations with lifestyle and other factors in women in a large UK prospective cohort.
    Blanks R; Burón Pust A; Alison R; He E; Barnes I; Patnick J; Reeves GK; Floud S; Beral V; Green J
    Int J Cancer; 2019 Aug; 145(3):728-734. PubMed ID: 30694563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the bowel-screening programme on the diagnosis of colorectal cancer in Ayrshire and Arran.
    Roxburgh CS; McTaggart F; Balsitis M; Diament RH
    Colorectal Dis; 2013 Jan; 15(1):34-41. PubMed ID: 22632378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
    Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
    Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
    Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
    Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression rates of colorectal cancer by Dukes' stage in a high-risk group: analysis of selective colorectal cancer screening.
    Wong JM; Yen MF; Lai MS; Duffy SW; Smith RA; Chen TH
    Cancer J; 2004; 10(3):160-9. PubMed ID: 15285925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval colorectal cancer rates after Hemoccult Sensa and survival by detection mode for individuals diagnosed with colorectal cancer in Winnipeg, Manitoba.
    Decker KM; Nugent Z; Lambert P; Biswanger N; Singh H
    PLoS One; 2018; 13(9):e0203321. PubMed ID: 30180176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screen-detected colorectal cancers show improved cancer-specific survival when compared with cancers diagnosed via the 2-week suspected colorectal cancer referral guidelines.
    Courtney ED; Chong D; Tighe R; Easterbrook JR; Stebbings WS; Hernon J
    Colorectal Dis; 2013 Feb; 15(2):177-82. PubMed ID: 22709315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study.
    Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG
    Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with symptom- and screening-detected colorectal cancer.
    Brenner H; Jansen L; Ulrich A; Chang-Claude J; Hoffmeister M
    Oncotarget; 2016 Jul; 7(28):44695-44704. PubMed ID: 27213584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.